drugset

drugset / Trial / NCT00004939

Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy

NCT00004939 ↗

Phase 3 Completed 34 enrolled National Center for Research Resources (NCRR) Mayo Clinic · collab

RandomizedDouble-blindTreatment

Summary

OBJECTIVES: I. Assess the efficacy of 3,4-diaminopyridine in patients with stable chronic demyelinating polyneuropathy.

Timeline

Start: 1996-08
Primary completion: —
Completion: 1996-08

Publications

Background Russell JW, Windebank AJ, Harper CM Jr. Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine. Mayo Clin Proc. 1995 Jun;70(6):532-9. doi: 10.4065/70.6.532.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amifampridine	Small molecule	—	Oral

Indications